ER: Of course many things go from bad to worse and if, in fact, Dr Makary's FDA reveals itself as more antithetical to Leronlimab than the previous FDA, I will accept the reality that LL will never be granted BTD or any form of approval during the pendency of Makary's administration. So far, however, based on Makary's bio at Johns Hopkins and his public statements that he wants to get breakthrough new drugs approved faster, I am not yet ready to conclude that we and LL will very soon be yearning for the gentle mercies of the previous FDA.